Egrifta (Tesamorelin) and Acetaminophen: The Drug Interaction Explained

Does Tesamorelin Interact with Acetaminophen?

There is no direct, mechanism-based pharmacokinetic interaction between tesamorelin and acetaminophen in the traditional sense of one drug blocking or inducing an enzyme that metabolizes the other. Tesamorelin works by binding pituitary growth hormone-releasing hormone (GHRH) receptors to stimulate endogenous growth hormone (GH) secretion. Acetaminophen is processed primarily by hepatic glucuronidation and sulfation, with a minor but toxicologically important fraction (~5-10%) converted to the reactive metabolite NAPQI by CYP2E1 and CYP3A4.

The concern here is not a classic drug-drug interaction. It is cumulative hepatic burden.

Why the Liver Is the Shared Concern

Women living with HIV on antiretroviral therapy (ART) already carry a significant hepatic load. Many ART regimens, including integrase strand-transfer inhibitors and older NRTIs, are associated with transaminase elevations in 5-15% of patients. Adding tesamorelin raises IGF-1 levels, and elevated IGF-1 has been associated with changes in hepatic lipid metabolism and, in some patients, mild transaminase shifts. Then adding even moderate daily acetaminophen on top of that creates a three-layer hepatic scenario your clinician needs to know about.

Tesamorelin's Effect on Hepatic Metabolism

Growth hormone itself modulates the expression of several hepatic cytochrome P450 enzymes. In women specifically, endogenous GH pulses are more frequent and of higher amplitude than in men, and exogenous GH-axis stimulation can meaningfully shift CYP3A4 and CYP2C activity. Because CYP3A4 contributes to NAPQI formation from acetaminophen at higher doses, a tesamorelin-driven increase in CYP3A4 activity is theoretically possible. This is not confirmed in direct human PK studies pairing these two drugs, but the biology is plausible enough to warrant caution.

A practical three-tier framework for women on tesamorelin who need pain relief:

1. Tier 1 (preferred): Topical diclofenac, ice/heat, physical therapy. No hepatic load.
2. Tier 2 (acceptable with monitoring): Acetaminophen at 1,000-2,000 mg/day total, short duration, confirmed normal LFTs.
3. Tier 3 (avoid or use only with specialist guidance): Acetaminophen above 2,000 mg/day, chronic daily use, or any use when ALT/AST is more than 2x the upper limit of normal.

What Tesamorelin Is, and Who Gets It

Tesamorelin (brand name Egrifta SV) is a synthetic analog of human GHRH. The FDA approved tesamorelin in 2010 specifically for reducing excess abdominal fat (visceral adiposity) in adults living with HIV-associated lipodystrophy. The approved dose is 2 mg subcutaneously once daily.

HIV-associated lipodystrophy causes fat to accumulate around the abdomen and trunk while the face, limbs, and buttocks lose fat. This is a metabolic consequence of both HIV itself and older antiretroviral drugs, particularly thymidine-analog NRTIs like stavudine and zidovudine.

How Common Is This in Women?

Women living with HIV develop lipodystrophy at rates comparable to or higher than men, yet they were significantly underrepresented in the key tesamorelin trials. In the LIPO-010 phase 3 trial, women made up approximately 20% of enrolled participants. This means most of the efficacy and safety data are extrapolated from a predominantly male cohort. The FDA label does not report sex-stratified subgroup analyses for liver enzyme changes, which is a real evidence gap worth naming plainly.

Metabolic Differences That Matter for Women

Women with HIV-associated lipodystrophy often present with a different phenotype than men. Visceral fat accumulation in women is frequently compounded by menopause-associated central adiposity, insulin resistance related to polycystic ovary syndrome (PCOS), and hormonal shifts across the perimenopause transition. IGF-1 levels are already lower in women than men at baseline and decline further after menopause, which means tesamorelin-driven IGF-1 increases may be proportionally larger in postmenopausal women. Whether that amplifies the hepatic signal from acetaminophen is unknown.

How Acetaminophen Is Metabolized (and Where It Goes Wrong)

At standard doses (325-650 mg every 4-6 hours, not exceeding 3,000-4,000 mg per day in healthy adults), acetaminophen is safe for most people. The majority is conjugated by UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) into non-toxic, water-soluble metabolites excreted in urine.

The danger lies in saturation. When doses climb, or when glucuronidation capacity is reduced by nutritional depletion, alcohol use, or liver disease, a larger fraction of acetaminophen is shunted to CYP2E1 and CYP3A4, producing NAPQI. NAPQI is rapidly neutralized by hepatic glutathione under normal conditions. Deplete glutathione, and NAPQI binds covalently to hepatocyte proteins, causing dose-dependent necrosis.

Women and Acetaminophen Pharmacokinetics

Sex differences in acetaminophen PK are real and clinically relevant. Women have higher rates of acetaminophen glucuronidation than men, which is generally protective. However, women also have lower average body weight, lower lean body mass, and lower total body water, meaning equivalent weight-based doses produce higher peak plasma concentrations. Women account for a disproportionate share of acetaminophen-related acute liver failure presentations in some registry data.

What "Hepatic Toxicity Overlap" Actually Means Here

The phrase "hepatic toxicity overlap" in DDI databases flags these two drugs together not because one changes the metabolism of the other in a proven mechanistic pathway, but because:

• Tesamorelin's GH-axis effects can cause mild, transient transaminase rises.
• Acetaminophen's NAPQI pathway is the dominant cause of drug-induced liver injury (DILI) in the United States.
• Women with HIV may already have hepatic inflammation from the virus, from ART, or from co-infections like hepatitis C.
• Nutritional deficits and lower glutathione reserves are common in women with HIV, narrowing the margin for NAPQI neutralization.

Specific Monitoring: What Your Clinician Should Check

The Egrifta SV prescribing information recommends monitoring IGF-1 levels every 6 months and adjusting the dose if IGF-1 exceeds age- and sex-normalized upper limits. It does not specify a liver enzyme monitoring schedule, but standard HIV care guidelines recommend periodic LFT assessment as part of routine ART monitoring.

A reasonable monitoring plan for a woman on tesamorelin who takes acetaminophen regularly:

| Timepoint | Test | |---|---| | Baseline (before starting tesamorelin) | ALT, AST, total bilirubin, alkaline phosphatase, IGF-1 | | 3 months after starting tesamorelin | ALT, AST, IGF-1 | | Every 6 months thereafter | ALT, AST, IGF-1, full metabolic panel | | Any time acetaminophen > 2,000 mg/day for > 5 days | ALT, AST |

If ALT or AST rises above 3x the upper limit of normal, acetaminophen should be stopped and tesamorelin continued only after consultation with a hepatologist or infectious disease specialist.

Women-Specific Conditions That Increase Risk

Perimenopause and Menopause

Perimenopausal and postmenopausal women with HIV face compounded metabolic challenges. Estrogen loss accelerates visceral fat accumulation, worsens insulin resistance, and reduces hepatic antioxidant capacity. This is the same population most likely to be on tesamorelin for lipodystrophy, and also the group most likely to reach for over-the-counter acetaminophen for joint pain, sleep disruption, and headaches common in the menopausal transition.

PCOS

Young women with HIV and PCOS have a dual burden of insulin resistance and androgen excess. Tesamorelin raises IGF-1, and IGF-1 is known to amplify ovarian androgen production in PCOS. Women with PCOS on tesamorelin should have their androgen levels and menstrual cycle regularity monitored, particularly if acetaminophen use is chronic, because systemic inflammation from liver stress can further disrupt ovulatory function.

Hepatitis C Coinfection

Approximately 25% of women living with HIV in the United States are coinfected with hepatitis C. Any degree of hepatic fibrosis from HCV dramatically lowers the threshold at which acetaminophen becomes harmful. For women with HIV/HCV coinfection on tesamorelin, the acetaminophen ceiling drops further, and NSAIDs (if renal function permits) or topical analgesics should be the first-line choice for pain.

Pregnancy, Lactation, and Contraception: Required Reading

Tesamorelin is FDA Pregnancy Category X. This is not a gray-zone safety designation. Category X means that animal or human data show fetal abnormalities, and the risks of use during pregnancy clearly outweigh any benefit. The Egrifta SV prescribing information states that tesamorelin should not be used during pregnancy and should be discontinued immediately if a patient becomes pregnant.

Contraception Requirement

Any woman of reproductive potential prescribed tesamorelin must use effective contraception. The prescribing information does not specify a required contraceptive method, but given the Category X designation, a method with a failure rate below 1% per year (intrauterine device, progestin implant, or tubal ligation) is clinically appropriate. HIV care guidelines from the CDC support long-acting reversible contraception (LARC) as preferred for women with HIV who do not desire pregnancy, both for reliability and to avoid drug interactions with oral contraceptives that are common with certain ART regimens.

Lactation

Tesamorelin has not been studied in lactating women. The prescribing information states that it is unknown whether tesamorelin is excreted in human milk. Because HIV itself is transmissible through breast milk and current CDC and WHO guidance advises women with HIV in high-income settings to formula feed when safe, the question of tesamorelin during lactation is largely moot in the US context. Women in low-resource settings where breastfeeding is necessary for infant survival should be managed in consultation with an HIV specialist and the tesamorelin should be withheld.

Trying to Conceive

Women with HIV who are trying to conceive should discontinue tesamorelin before attempting pregnancy. Given that visceral adiposity itself impairs fertility and tesamorelin reduces visceral fat, discontinuation may temporarily worsen the metabolic environment. Fertility planning in this setting requires a coordinated approach between an HIV specialist, a reproductive endocrinologist, and, where relevant, an obesity medicine clinician.

Acetaminophen in Pregnancy

Acetaminophen has historically been considered the analgesic of choice during pregnancy. That consensus is being revisited. A 2021 consensus statement signed by 91 scientists and clinicians flagged prenatal acetaminophen exposure as a potential risk factor for neurodevelopmental disorders, urogenital anomalies, and reproductive outcomes, calling for precautionary guidance. The evidence is not definitive, but it is substantial enough that the FDA issued a Drug Safety Communication in 2023 advising pregnant women to use the lowest effective dose for the shortest possible time. Since tesamorelin is contraindicated in pregnancy, the clinical scenario of a woman on both drugs simultaneously should not occur if contraception guidance is followed.

Drug Interactions Beyond Acetaminophen: The Bigger Picture for Women on Egrifta

Tesamorelin's GH-stimulating mechanism creates several clinically meaningful interactions relevant to women's health.

Insulin and Antidiabetic Agents

GH is counter-regulatory to insulin. Tesamorelin raises fasting glucose and insulin resistance in a dose-dependent pattern. The LIPO-010 trial showed a modest but statistically significant increase in fasting glucose versus placebo over 26 weeks. Women with pre-existing insulin resistance from PCOS, postmenopausal metabolic changes, or ART-associated diabetes need glucose monitoring every 3 months on tesamorelin, with metformin or GLP-1 receptor agonist dose adjustments as clinically indicated.

Corticosteroids

Corticosteroids blunt GH secretion and may reduce tesamorelin's efficacy. Women with asthma, lupus, or rheumatoid arthritis who take systemic steroids may see reduced visceral fat reduction on tesamorelin. The interaction is pharmacodynamic, not pharmacokinetic.

Estrogen and Oral Contraceptives

Oral estrogens increase GH resistance at the hepatic level by reducing IGF-1 production. Women on combined oral contraceptives or high-dose oral estrogen hormone therapy may have a blunted IGF-1 response to tesamorelin compared with women on transdermal estrogen or no estrogen. This estrogen-route effect on IGF-1 is well documented and is why postmenopausal women using oral versus transdermal HRT show different IGF-1 levels on exogenous GH therapy. Transdermal estrogen is preferred for women on tesamorelin who need hormone therapy.

Who This Is Right For, and Who Should Pause

Women Who Can Take Acetaminophen While on Tesamorelin (with Monitoring)

• Normal baseline LFTs (ALT/AST within reference range)
• No hepatitis B or C coinfection
• No current alcohol use
• Acetaminophen dose below 2,000 mg/day, used for fewer than 7 consecutive days
• IGF-1 within age- and sex-adjusted normal limits on tesamorelin
• No nutritional depletion or low body weight that could reduce glutathione reserves

Women Who Should Avoid or Strictly Limit Acetaminophen

• Active hepatitis C or hepatitis B coinfection
• Baseline ALT or AST above 2x the upper limit of normal
• Current alcohol use (even light-to-moderate)
• Significant malnutrition or body weight below normal
• IGF-1 above the upper normal limit on tesamorelin (suggests hepatic GH effect is supraphysiological)
• Any signs of ART-related hepatotoxicity

For pain in the women-who-should-avoid category, topical analgesics (topical diclofenac 1% gel, topical lidocaine), physical therapy, and low-dose muscle relaxants with lower hepatic burden are reasonable alternatives. NSAIDs carry their own risks in women with HIV, particularly renal toxicity in those with nephropathy, so they are not automatically safer.

Patient Counseling: The Conversation Your Clinician Should Have with You

Direct guidance you can bring to your next appointment:

1. Tell every provider you are on tesamorelin. It changes how common medications behave in your body.
2. Check acetaminophen-containing products. Many OTC cold medications, sleep aids, and combination pain relievers contain acetaminophen. Stacking products can push you over safe thresholds without realizing it.
3. Get a baseline liver panel before starting tesamorelin if you have not had one in the last 6 months.
4. Report any nausea, right-upper-quadrant discomfort, yellowing of skin or eyes, or unusual fatigue immediately. These may indicate liver stress.
5. Do not take more than 2,000 mg of acetaminophen daily while on tesamorelin, and aim for the lowest dose that controls your symptoms.

As The Menopause Society's 2023 position statement on metabolic health notes regarding polypharmacy in midlife women: "Clinicians should conduct a systematic medication review at every visit, with particular attention to hepatic and metabolic burden in women with multiple comorbidities."